Nektar Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Nektar Therapeutics has a total shareholder equity of $48.9M and total debt of $97.8M, which brings its debt-to-equity ratio to 200.1%. Its total assets and total liabilities are $308.0M and $259.1M respectively.
Key information
200.1%
Debt to equity ratio
US$97.83m
Debt
| Interest coverage ratio | n/a |
| Cash | US$244.50m |
| Equity | US$48.88m |
| Total liabilities | US$259.08m |
| Total assets | US$307.97m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0UNL's short term assets ($286.5M) exceed its short term liabilities ($67.6M).
Long Term Liabilities: 0UNL's short term assets ($286.5M) exceed its long term liabilities ($191.5M).
Debt to Equity History and Analysis
Debt Level: 0UNL has more cash than its total debt.
Reducing Debt: 0UNL's debt to equity ratio has increased from 21.6% to 200.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0UNL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0UNL has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 22.2% each year.